From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
CONCLUSION: New and more effective histone deacetylases inhibitors gived alone or in combination are a solution for an improved response to the treatment of patients with relapsed/refractory lymphoproliferative disorders.
PMID: 28933264 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Immunotherapy | Lymphoma | Myeloma | Study | T-cell Lymphoma